# Inscopix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inscopix

- Industry: Biotechnology
- Headquarters: Mountain View, US
- Website: www.inscopix.com
- Total disclosed funding: $10M
- Latest round: Series A (Aug 25, 2016)
- Investors on record: 4

## About

Inscopix, Inc., based in the US, specializes in advanced technologies for neural circuit imaging, enhancing understanding of brain functions and aiding in the development of therapies for neurological and psychiatric disorders.Inscopix, Inc. was founded in 2011 and operates from Mountain View, California, US. The company focuses on innovative solutions for brain function research, with a strategic pivot towards developing tools for various neurological conditions. Kunal Ghosh serves as both the CEO and Founder. In November 2022, the company completed a Series A funding round, raising USD 10.00 mn led by Playground Ventures, with participation from AME Cloud Ventures and Floodgate. Inscopix has completed a total of 3 deals, with the most recent deal occurring on November 8, 2022, when it was acquired by Bruker Corporation, although financial terms of the acquisition were not disclosed.Inscopix, Inc. specializes in advanced neural circuit imaging technologies designed to enhance the understanding of brain function and facilitate the development of therapies for neurological and psychiatric disorders. The company’s flagship products include the nVue, nVoke, nVista, and nVista 2P systems, which provide dual-color and single-color imaging capabilities along with optogenetic manipulation of neural circuits. These products are utilized in academic and biopharmaceutical research settings, enabling groundbreaking insights into conditions such as depression, Parkinson's disease, Alzheimer's disease, and PTSD. Inscopix's solutions are marketed globally, with key markets including North America, Europe, and Asia, catering to a diverse clientele that includes prominent institutions, pharmaceutical companies, and research laboratories.Inscopix generates revenue primarily through direct sales of its innovative imaging systems and associated software solutions to research institutions and pharmaceutical companies. The company operates on a B2B model, facilitating transactions that often involve customized agreements tailored to the specific needs of its clients. These transactions may include both one-time purchases and ongoing subscription services for software analysis tools, ensuring continued access to updates and support as part of the overall package. The company's offerings are positioned as premium solutions within the neuroscience research market, reflecting their advanced technological capabilities and the value they deliver to end users.The acquisition of Inscopix, Inc. by Bruker Corporation in November 2022 will enhance Bruker’s reputation as a leader in technology for in vivo brain functional imaging. The integration is expected to bolster the development of advanced multiphoton microscopes and preclinical MRI systems. Moving forward, Inscopix plans to continue expanding its product offerings and market reach, although specific information on upcoming products or geographic expansions has not been disclosed.

## Funding rounds

- Series A, Aug 25, 2016, $10M — Floodgate, AME Cloud Ventures, Playground Ventures
- Seed, Aug 1, 2011 — F-Prime Capital, Floodgate

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Seed
- Floodgate (https://capitalatlas.ai/funds/floodgate) — Seed, Series A
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Series A